Empagliflozin Lowers Cardiovascular Death and Mortality in High-Risk Patients With Type 2 Diabetes
Researchers of a large, randomized trial evaluated the cardiovascular effects of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes at high cardiovascular risk.
Diabetes Treatment Guidelines for Older Adults: Tailoring Care Based on Health, Aging, and Comorbidities
This guideline provides clinical practice guidance for treating diabetes in older adults, particularly those over the age of 65, as type 2 diabetes is becoming more prevalent in this age group.
Expanding CGM Use in Diabetes: Standardized Metrics, Personalized Goals, and A1C Complementation
The adoption of continuous glucose monitoring (CGM) is growing among both type 1 and type 2 diabetes populations, but its clinical use remains low.
Updated Hypoglycemia Guidelines: Key Recommendations on CGM, Insulin, Education, and Prevention
Hypoglycemia is a common concern for people with diabetes, especially those using insulin and sulfonylureas, as these medications increase the risk.
ADA Updates Standards: Expanded CGM Use, Personalized Care, and Improved Access
The American Diabetes Association (ADA) has updated its standards of care to reflect the growing role of diabetes technology in improving patient outcomes.
Early CKD Detection: Key Steps to Prevent Kidney Failure and Cardiovascular Risks
Chronic kidney disease (CKD) is a major health concern, increasing risks for mortality, cardiovascular issues, and kidney failure. Early identification and management are key to reducing these risks.
